|Home | About | Journals | Submit | Contact Us | Français|
Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive clinical benefit from this combination. The purpose of this single-arm phase II study was to determine the efficacy and safety of the dual-targeting combination of lapatinib and bevacizumab. Women with HER2-overexpressing advanced breast cancer received 1,500 mg oral lapatinib daily plus 10 mg/kg IV bevacizumab every 2 weeks. The primary endpoint was progression-free survival (PFS) at week 12; secondary endpoints included overall tumor response rate (ORR), clinical benefit rate (CBR), duration of response, time-to-response, PFS, and safety. Circulating tumor cells (CTC) and circulating endothelial cells (CEC) were measured at baseline and during study treatment as potential response markers. Fifty-two patients with stage IV disease were enrolled. The 12-week investigator-assessed PFS rate was 69.2% (95% confidence interval [CI]: 54.9, 81.3). Median PFS was 24.7 weeks (95% CI: 20.4, 35.1), and the CBR was 30.8% (95% CI: 18.7, 45.1). Of 45 patients with measurable disease, 6 were determined to have a partial response per Response Evaluation Criteria in Solid Tumors (ORR: 13.3%; 95% CI: 5.1, 26.8). The most common adverse events (AEs) included diarrhea, rash, and fatigue; most of these were either grade 1 or 2. Clinical responses were correlated with decreases in CTC and CEC. Lapatinib plus bevacizumab was active in patients with HER2-overexpressing breast cancer. The AE profile of the combination was consistent with the known profiles for these agents.
Approximately 20–30% of all breast cancers overexpress the human epidermal growth factor receptor-2 (HER2) oncoprotein [1, 2]. Although the prognosis for early stage HER2-overexpressing cancers has improved dramatically with the use of the monoclonal antibody trastuzumab in the adjuvant setting, both acquired and intrinsic resistance limit effective treatment of this highly aggressive subset of breast cancer in the metastatic setting [3, 4]. A minority (15–26%) of patients with HER2-overexpressing metastatic tumors respond to first-line trastuzumab monotherapy, and most initial responders will develop disease progression within 1 year [5, 6]. Therefore, novel and rational strategies targeting HER2-driven breast cancers are needed.
Of the identified angiogenic factors, vascular endothelial growth factor (VEGF) is the most potent and specific regulator of both normal and pathologic angiogenesis . In preclinical studies, HER2-overexpression was associated with upregulation of VEGF in human breast cancer cell lines , and increased VEGF RNA and protein expression in human breast cancer xenograft models . Moreover, in a large clinical cohort, patients whose tumors overexpressed HER2 and upregulated VEGF had worse survival compared with patients whose tumors overexpressed HER2 but not VEGF . These data raise the possibility that aggressive phenotypes of HER2-overexpressing breast cancers may be mediated by VEGF and provide a rationale for combining anti-HER2 and anti-VEGF therapies in the treatment of HER2-overexpressing breast cancers.
In HER2-overexpressing human breast cancer xenografts, the combination of trastuzumab and bevacizumab, an anti-VEGF-A monoclonal antibody, reduced xenograft tumor volume compared with single-agent controls . A phase II study presented at the San Antonio Breast Cancer Symposium in 2009 treated 50 patients with HER2-overexpressing metastatic breast cancer (MBC) in the first-line setting with the combination of trastuzumab and bevacizumab, reported a clinical benefit rate (CBR) of 60%, median time to progression (TTP) of 7.1 months, and a median overall survival (OS) of 43.8 months .
Lapatinib is a potent and specific reversible small molecule dual tyrosine kinase inhibitor (TKI) of both HER2 and epidermal growth factor receptor (EGFR). In trastuzumab-refractory disease, lapatinib plus capecitabine improved response and TTP compared with capecitabine alone [12, 13]. Among 140 patients who had not previously received chemotherapy or trastuzumab for HER2-positive disease, lapatinib combined with pazopanib, a small-molecule angiogenesis inhibitor of the VEGF receptor (VEGFR), led to a 12-week progression-free survival (PFS) of 84.1% compared to 63% with lapatinib monotherapy. A subsequent analysis on combining higher doses of lapatinib and pazopanib revealed no difference in response rates compared with the lower-dose arm but demonstrated a significant increase in serious toxicity .
In this study, a novel approach that combined lapatinib with bevacizumab to treat advanced HER2-overexpressing breast cancer was examined. In addition, circulating tumor cells (CTC) and circulating endothelial cells (CEC) were measured at baseline and during study treatment as potential early markers of response.
This phase II open-label multicenter study (EGF103890, NCT00444535) enrolled women aged ≥18 years with histologically confirmed locally advanced stage III/IV breast cancer that overexpressed HER2 (either 3+ by immunohistochemistry [IHC] or positive fluorescence in situ hybridization [FISH+]). Patients were eligible if they had: an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; adequate hepatic, renal, and hematologic function; and a cardiac ejection fraction within the institutional normal range. Prior anticancer therapy for MBC, including prior HER2- and VEGF-directed, was permitted but not required. Patients with recent major surgery, wound healing difficulties, proteinuria, or significant vascular, cardiac, and/or bleeding disorders were excluded. Women of childbearing potential were required to have a negative serum pregnancy test at baseline and to use appropriate contraception. The institutional review board for each participating institution approved the study protocol. This study was conducted in accordance with good clinical practice, all applicable regulatory requirements, and the guiding principles of the Declaration of Helsinki. All patients provided written informed consent before enrollment.
Eligible patients received study treatment (1,500 mg oral lapatinib daily plus 10 mg/kg bevacizumab IV every 2 weeks) until disease progression, withdrawal due to unacceptable toxicity, or withdrawal of consent. Dose delays of up to 2 weeks and/or dose reductions were allowed to manage toxicity. Lapatinib was discontinued in patients with symptomatic decreases in left ventricular ejection fraction (LVEF). Patients with asymptomatic LVEF decreases continued therapy and had a repeat evaluation within 2 weeks. If the abnormal LVEF decrease was confirmed, therapy was temporarily discontinued and could be restarted at a lower dose following event resolution.
The treatment safety profile was evaluated after the first 10 patients received 6 weeks of study treatment. If >4 dose-limiting toxicities (DLTs) were reported, the dose of lapatinib was reduced by 500 mg per day and the combination was reevaluated in ten additional patients. If ≤3 DLTs were observed, the study was opened to enrollment at full dose.
Based on a reported 4-month PFS rate of 41% among trastuzumab-refractory patients receiving single-agent lapatinib, and to mirror the design of the lapatinib and pazopanib combination trial, the primary endpoint of this study was PFS rate at week 12 [15, 16]. Secondary endpoints included overall tumor response rate (ORR; complete or partial response confirmed ≥4 weeks from first response), CBR (confirmed complete response [CR] + partial response [PR] or stable disease for ≥24 weeks), duration of response, time to response, PFS, and safety. An exploratory analysis correlating baseline and on-treatment changes in CTCs and CECs with efficacy outcomes was also performed.
AEs were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0. Patients were evaluated prior to each bevacizumab infusion and had a thorough physical exam. Echocardiograms or multiple-gated acquisition scans were performed at week 8 and every 12 weeks thereafter. A cardiac event was defined as a symptomatic decline in LVEF, or an asymptomatic ≥20% decrease in LVEF below the institution’s lower limit of normal.
Blood for CTC and CEC analysis was obtained at: baseline: weeks 2, 6, 8, and 12; and every 12 weeks until the end of study treatment. CTCs were measured by 2 independent methods: CellSearch® (Veridex, LLC, Raritan, NJ)  and immunomagnetic enrichment followed by flow cytometry (IE/FC) . In brief, for IE/FC, cells were analyzed using IE with anti-EpCAM antibody-conjugated iron oxide nanoparticles followed by fluorescence-activated cell sorting (FACS) analysis for quantification. CTC were defined as EpCAM-positive, CD45-negative, and nucleated.
CEC were evaluated using a modified FC assay . Following red blood cell lysis, CEC-related cell populations were identified by 4-color FC using a FACSCalibur™ flow cytometer (BD Biosciences, San Jose, CA). CECs were defined as CD34-positive and leukocyte common antigen (CD45)-negative. In addition, total CECs were defined as CD31-positive or CD146-positive and progenitor CEC as CD31-positive and CD133-positive.
The study was designed to lead to a decision between 2 prespecified hypotheses on the probability (P) of the 12-week PFS rate. The null hypothesis (i.e., H0: P = 40%) was considered to reflect a PFS rate that was not a clinically significant benefit over existing therapies. The alternative hypothesis (i.e., HA: P = 60%) was considered to be a clinically significant improvement. Enrollment of 52 patients provided 84% power to evaluate these hypotheses using a 1-sided exact binomial test procedure. A minimum of 28 patients (factoring an additional 3% for a 1-sided type I error) were required to reach week 12 without disease progression to reject H0.
All efficacy analyses were conducted on the intent-to-treat population. Efficacy analyses were based on the investigator’s evaluation of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) . The primary endpoint, 12-week PFS rate, was defined as the percentage of patients with no evidence of disease progression or death due to any cause for a minimum of 77 days. Patients with unknown or missing responses at week 12 or withdrawing from treatment by week 12 due to an AE were considered progressors. Patients with unknown or missing responses at week 12 followed by a nonprogressive disease response were evaluated based on response. PFS was defined as time from randomization until disease progression or death due to any reason.
CTC and CEC results were correlated to CBR and PFS. CTCs, measured using the Veridex and IE/FC methods, were tested for correlation at each time point using Spearman’s test. CTC and CEC values (at each time point and change from baseline) were tested for association with CBR using the Wilcoxon rank-sum test. For correlation with PFS, Cox proportional hazards models were used. In the PFS models, CTC values at baseline, week 2, and weeks 6–8 were dichotomized into (0, 1) variables using the accepted cutoff values for CellSearch (cells/7.5 mL = 5); IE/FC and endothelial cells were modeled using cell counts as continuous variables (log scale). Additional PFS models evaluated change from baseline for CTC and CEC as a dichotomous variable defined as increase or no increase at each time point.
The first 10 patients were enrolled between March 2007 and May 2007. A total of 54 AEs were reported; 53 (98%) were grade 1 or 2. As the initial 10-patient cohort had only 1 DLT (grade 3 skin rash with grade 1 fever), the study was opened to full recruitment.
This trial enrolled 52 patients between March 2007 and April 2008 (Table 1). All patients had stage IV disease, and 51 of these patients were either FISH-positive or IHC 3+ for HER2-overexpression. Most patients had received prior chemotherapy (96%) and/or prior trastuzumab (90%). These patients were considered heavily pretreated, with a median of 3 prior chemotherapy regimens (range 0–12) for metastatic disease as well as a median prior exposure of 30.7 weeks to lapatinib (range 3.3–52.3; Table 1) and 84.1 weeks to trastuzumab in the metastatic setting (range 5.3–434.3; Table 1).
Lapatinib was generally well tolerated (mean daily dose, 1,497 mg/d) with dose reductions to 1,250 mg/d in 3 (6%) patients and to 1,000 mg/d in 2 (4%) patients for toxicity. Lapatinib was withheld for ≥24 h in 11 patients and bevacizumab was delayed in 8 patients, most frequently to manage diarrhea and hypertension, respectively.
The most common AEs were diarrhea, rash, fatigue, nausea, headache, and epistaxis, reflecting the known safety profile of both drugs (Table 2); most events were either grade 1 or 2. AEs led to treatment discontinuation in 5 (10%) patients: grade 3 rash with grade 1 fever; grade 3 alanine aminotransferase/aspartate aminotransferase (ALT/AST) elevation; grade 2 left ventricular dysfunction; grade 3 hypertension; and grade 2 anorexia with grade 2 fatigue, and grade 1 nausea.
One patient reported grade 3 diarrhea that lasted 3 days; lapatinib was withheld for 6 days and restarted at 1,250 mg/d without recurrent symptoms.
Two patients reported grade 3 rash. The first patient developed an extensive grade 3 rash accompanied by a grade 1 fever after 10 days of study treatment. Study treatment was discontinued and the rash resolved with oral steroids. The second patient experienced a grade 3 rash after 19 days of study treatment; lapatinib was withheld then restarted at 1,250 mg/d on day 33. The patient withdrew from the study on day 40 for personal reasons.
Five (10%) patients experienced a grade 1 or 2 decrease in LVEF; 1 patient discontinued study treatment due to a grade 2 decline in LVEF. Two of these events coincided with disease progression; 1 coincided with a viral syndrome that led to treatment withdrawal; and the remaining 2 events resolved at the next evaluation. All 5 patients had received prior anthracyclines and trastuzumab.
Grade 3 ALT/AST elevation was reported in 1 patient after 127 days on study. Study treatment was withheld on day 136, restarted at full dose on day 141, and dose-reduced to 1,000 mg/d on day 153. The elevation persisted and the patient was permanently withdrawn from study on day 169. Grade 4 hyperbilirubinemia was reported in 1 patient 2 weeks after treatment discontinuation due to disease progression.
Hypertension was reported in 12 (23%) patients; 10 were grade 1 or 2, and 2 cases were grade 3 leading to treatment withdrawal in 1 patient.
Grade 4 hydronephrosis was reported in 1 patient after 148 days of study treatment attributed to disease progression. Grade 3 gastrointestinal hemorrhage, gastritis, and anemia was reported in 1 patient 10 days after treatment withdrawal due to disease progression.
The investigator-assessed 12-week PFS rate was 69.2% based on 36 patients not progressing by week 12. The median PFS was 24.7 weeks, and the CBR was 30.8%. Of 45 patients with measurable disease, 6 were determined to have a PR per RECIST (ORR: 13.3%; Table 2). Five patients responded by week 6; the sixth patient responded by week 12. Responses were durable, lasting 43, 120, 127, 191, 247, and 455 days; responses of 43, 127, and 455 days were ongoing and censored at the last radiology assessment before reporting (Fig. 1).
Correlation between Veridex and IE/FC was statistically significant at each time point, with R values ranging from 0.37 to 0.42 (P < .05; n = 29–32). Low CTC levels by either assay were associated with CBR at weeks 6–8 (CellSearch: P = .023, n = 38; IE/FC: P = .032, n = 30) but not at baseline or week 2. Compared with baseline, CTC decrease by IE/FC at weeks 6–8 was associated with CBR (P = .0098, n = 28; Fig. 2a).
Shorter PFS was observed in patients with CTC ≥ 5 cells/7.5 mL by CellSearch (week 2, P = .0135, n = 43; Fig. 2b; weeks 6–8, P = .0036, n = 38). Patients with high levels of CTC by IE/FC at weeks 6–8 were also found to have a shorter PFS (P = .0088; n = 34). An increase in CTC from baseline to weeks 6–8 (>0 vs. ≤0) by either assay was associated with decreased PFS (CellSearch: P = .0033, n = 34; IE/FC: P = .0179, n = 28).
Although change in total CEC did not correlate with CBR or PFS, a decrease in endothelial progenitor cells (CD-31-positive and CD133-positive) at weeks 6–8 was associated with CBR (P = .021, n = 25).
Although other trials have examined the combination of anti-HER2 and anti-VEGF agents in HER2-driven breast cancer treatment, this study is the first to report results on an oral TKI and a monoclonal antibody. Moreover, this is the only phase II study to describe combination therapy in a heavily pretreated population. In this report, daily lapatinib plus bevacizumab resulted in a 12-week PFS rate of 69.2%, and a CBR and ORR of 30.8 and 13.3%, respectively. Many observed responses were durable and the median PFS was 24.7 weeks. These data are provocative considering that 90% of the patients received a median of 84.1 weeks of prior trastuzumab in any setting.
Other studies have also shown promising activity with a combined anti-HER2 and anti-VEGF approach, although in the trastuzumab-naive first-line metastatic setting, making direct comparisons with the present trial is difficult. Hurvitz et al.  reported final results of a phase II trial of 50 patients with locally recurrent or metastatic HER2-overexpressing breast cancer receiving trastuzumab plus bevacizumab in the first-line metastatic setting that demonstrated an impressive CBR of 60% and a median 9.2-month TTP. Furthermore, a phase II trial investigating lapatinib and pazopanib randomized 1 cohort of patients to lapatinib versus lapatinib plus pazopanib as first-line therapy for HER2-overexpressing MBC; a second cohort received a higher dose of pazopanib combined with lapatinib without randomization. An analysis of the first cohort showed an improved response rate with the combination (36%) compared with lapatinib alone (22%); however, toxicities were noted when pazopanib was given at a higher dose .
In this trial, changes in CTCs, as measured by two independent assays, correlated with both CBR and PFS. These data confirm previous observations showing that CTC fluctuations in patients receiving systemic treatment for MBC are predictive of outcome [17, 21–23]. The 2 different methodologies showed relatively weak but statistically significant correlation with each other, suggesting that the 2 techniques are capable of recognizing overlapping cell populations. As the IE/FC method allows CTC isolation for molecular analysis, continued validation of this technique is of interest for future research.
Reproducible, reliable, and easily obtainable markers for response and resistance to antiangiogenic therapy are needed. This study demonstrates that in patients with HER2-positive disease who received bevacizumab in combination with lapatinib, CBR was associated with a decrease in CD133-positive CECs. This finding supports previous data in patients with MBC receiving bevacizumab and erlotinib that showed the magnitude of change in total CECs from weeks 0–3 predicted response at first assessment (P = .018) . CECs have been evaluated primarily as markers of angiogenesis; controversy exists regarding methodology, which cannot be addressed in the context of this small trial. Further validation of the role of CECs as early predictors of response in patients receiving antiangiogenic therapy is ongoing.
Clinical studies suggest that combined targeting of HER2 and VEGFR may be an effective strategy as treatment for HER2-overexpressing breast cancer but that toxicity may limit dose for some combinations. This approach may offer a new option for treating patients whose disease has progressed on or after trastuzumab and could be potentially used in an early stage setting to target intrinsically resistant disease. The phase III adjuvant BETH study comparing chemotherapy and trastuzumab to the same treatment with the addition of bevacizumab has completed accrual and is awaiting analysis . ECOG 1105 evaluated a similar approach as first-line therapy for MBC but closed early due to poor accrual .
Lapatinib monotherapy in patients previously treated with trastuzumab in the advanced setting has shown limited efficacy [15, 27]. In a recent phase II study randomizing patients with HER2-positive metastatic disease progressing on prior trastuzumab therapy to receive lapatinib versus lapatinib and trastuzumab, single-agent lapatinib led to a median PFS of 8.1 weeks and an ORR of 6.9% . Similarly, treatment with bevacizumab alone in HER2-positive and HER2-negative disease has led to ORRs less than 7% . The present study results suggest that the combination of lapatinib and bevacizumab may be more effective than lapatinib or bevacizumab alone in this setting and may be a nonchemotherapy alternative for some patients. The combination of lapatinib and trastuzumab also demonstrated improved efficacy compared with trastuzumab alone in the trial noted above . Other nonchemotherapy-based strategies for treating HER2-overexpressing tumors that progress on trastuzumab are being explored in ongoing clinical trials with encouraging results to date, including trastuzumab plus pertuzumab (a novel HER2 antibody) and the targeted immunotherapy trastuzumab DM-1 [30, 31].
Finding effective therapies for patients with resistant or refractory HER2-overexpressing breast cancer remains an important therapeutic goal. The combination of lapatinib and bevacizumab is a promising approach to the treatment of HER2-overexpressing disease and warrants further investigation in combination with chemotherapy in advanced disease. Identifying reliable markers that predict both resistance to anti-HER2 agents and response to anti-VEGFR therapies is necessary to optimize this treatment strategy.
This study was funded by GlaxoSmithKline (NCT00444535). All listed authors meet the criteria for authorship set forth by the International Committee of Medical Journal Editors. Editorial support in the form of editorial suggestions to draft versions of this article, assembling tables and figures, collating author comments, copyediting, fact checking, referencing, and graphic services was provided by Brad Imwalle, PhD, Antoinette Campo, and Tim Reilly at SCI Scientific Communications and Information. The authors would like to thank the patients who volunteered for this clinical trial and their families, friends, physicians, and research staff who cared for them.
Hope S. Rugo: Genentech, GlaxoSmithKline, and Roche have provided research funding to the University of California San Francisco. A. Jo Chien, Sandra X. Franco, Alexa Glencer, Janet Scott, Clifford Hudis, and Ben Nulsen have no conflicts of interest to disclose. Alison T. Stopeck serves as a consultant and/or an advisor for Genentech. Soumi Lahiri has received remuneration from GlaxoSmithKline. Michael C. Arbushites has received remuneration from, and holds stock in, GlaxoSmithKline. John W. Park has received remuneration from Genentech and Roche. Maura N. Dickler serves as a consultant and/or advisor for Genentech, GlaxoSmithKline, and Roche.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.